Evidence map›Paper›PMID 31387945›Full record

ArticleThe Journal of biological chemistry2019

A strategy for the selection of monovalent antibodies that span protein dimer interfaces.

Jamie B Spangler, Ignacio Moraga, Kevin M Jude, Christina S Savvides, K Christopher Garcia

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Catching a complex for optimal signaling.The Journal of biological chemistry · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jamie B SpanglerHoward Hughes Medical Institute, Stanford University School of Medicine, Stanford, California 94305 jamie.spangler@jhu.edu.ORCID 0000-0001-8187-3732
Ignacio MoragaHoward Hughes Medical Institute, Stanford University School of Medicine, Stanford, California 94305.ORCID 0000-0001-9909-0701
Kevin M JudeHoward Hughes Medical Institute, Stanford University School of Medicine, Stanford, California 94305.ORCID 0000-0002-3675-5136
Christina S SavvidesDepartment of Biology, Stanford University School of Medicine, Stanford, California 94305.ORCID 0000-0002-6606-1207
K Christopher GarciaHoward Hughes Medical Institute, Stanford University School of Medicine, Stanford, California 94305 kcgarcia@stanford.edu.ORCID 0000-0001-9273-0278
Howard Hughes Medical Institute · USStanford University · US

Funding

Structure-based engineering of immune cytokine signalingR01AI051321 · NIAID · STANFORD UNIVERSITY · PI Kenan Christopher GARCIA · 2002 to 2026
$5.6M
Structure, function and engineering of immune cytokine receptor signalingR37AI051321 · NIAID · STANFORD UNIVERSITY · PI GARCIA, KENAN CHRISTOPHER · 2013 to 2022
$4.2M
NIAID NIH HHS R01 AI051321NIAID NIH HHS R37 AI051321
6 · The paper itself

Abstract

Ligand-induced dimerization is the predominant mechanism through which secreted proteins activate cell surface receptors to transmit essential biological signals. Cytokines are a large class of soluble proteins that dimerize transmembrane receptors into precise signaling topologies, but there is a need for alternative, engineerable ligand scaffolds that specifically recognize and stabilize these protein interactions. Recombinant antibodies can potentially serve as robust and versatile platforms for cytokine complex stabilization, and their specificity allows for tunable modulation of dimerization equilibrium. Here, we devised an evolutionary strategy to isolate monovalent antibody fragments that bridge together two different receptor subunits in a cytokine-receptor complex, precisely as the receptors are disposed in their natural signaling orientations. To do this, we screened a naive antibody library against a stabilized ligand-receptor ternary complex that acted as a "molecular cast" of the natural receptor dimer conformation. Our selections elicited "stapler" single-chain variable fragments (scFvs) of antibodies that specifically engage the interleukin-4 receptor heterodimer. The 3.1 Å resolution crystal structure of one such stapler revealed that, as intended, this scFv recognizes a composite epitope between the two receptors as they are positioned in the complex. Extending our approach, we evolved a stapler scFv that specifically binds to and stabilizes the interface between the interleukin-2 cytokine and one of its receptor subunits, leading to a 15-fold enhancement in interaction affinity. This demonstration that scFvs can be selected to recognize epitopes that span protein interfaces presents new opportunities to engineer structurally defined antibodies for a broad range of research and therapeutic applications.

Indexed as

Amino Acid SequenceDimerizationEpitope MappingEpitopesHumansLigandsMolecular ConformationPeptide LibraryProtein BindingProtein EngineeringProtein MultimerizationSingle-Chain AntibodiesEpitopesLigandsPeptide LibrarySingle-Chain Antibodiesantibody engineeringcell signalingcytokinedimerizationdirected evolutionimmunologyinterleukin-2interleukin-4ligand-receptor interactionsstructural biology

Identifiers

PMID31387945
PMCPMC6755802
OpenAlexW2966351120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.